XOMA’s Acquisition of Royalty and Milestone Interest in Checkmate’s Vidutolimod from Kuros Biosciences

XOMA's Acquisition of Royalty and Milestone Interest in Checkmate’s Vidutolimod from Kuros Biosciences
Federica Tiefenthaler
Tagged:

Paul Hastings advised Xoma Corporation on the deal. Vischer advised Kuros Biosciences AG.Xoma Corporation, a biotechnology and pharmaceutical royalty aggregator, announced the acquisition of the royalty interest position…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Federica Tiefenthaler

Author: Federica Tiefenthaler

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here